SG11201402343SA - Method of treatment of tumors that are resistant to egfr therapies by egfr antibody cytotoxic agent conjugate - Google Patents

Method of treatment of tumors that are resistant to egfr therapies by egfr antibody cytotoxic agent conjugate

Info

Publication number
SG11201402343SA
SG11201402343SA SG11201402343SA SG11201402343SA SG11201402343SA SG 11201402343S A SG11201402343S A SG 11201402343SA SG 11201402343S A SG11201402343S A SG 11201402343SA SG 11201402343S A SG11201402343S A SG 11201402343SA SG 11201402343S A SG11201402343S A SG 11201402343SA
Authority
SG
Singapore
Prior art keywords
egfr
tumors
resistant
treatment
method
Prior art date
Application number
SG11201402343SA
Inventor
Julianto Setiady
Peter U Park
Thomas Chittenden
Original Assignee
Immunogen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to US201161562157P priority Critical
Priority to US201261639452P priority
Application filed by Immunogen Inc filed Critical Immunogen Inc
Priority to PCT/US2012/066205 priority patent/WO2013078271A1/en
Publication of SG11201402343SA publication Critical patent/SG11201402343SA/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
SG11201402343SA 2011-11-21 2012-11-21 Method of treatment of tumors that are resistant to egfr therapies by egfr antibody cytotoxic agent conjugate SG11201402343SA (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
US201161562157P true 2011-11-21 2011-11-21
US201261639452P true 2012-04-27 2012-04-27
PCT/US2012/066205 WO2013078271A1 (en) 2011-11-21 2012-11-21 Method of treatment of tumors that are resistant to egfr therapies by egfr antibody cytotoxic agent conjugate

Publications (1)

Publication Number Publication Date
SG11201402343SA true SG11201402343SA (en) 2014-06-27

Family

ID=48470279

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201402343SA SG11201402343SA (en) 2011-11-21 2012-11-21 Method of treatment of tumors that are resistant to egfr therapies by egfr antibody cytotoxic agent conjugate

Country Status (16)

Country Link
US (1) US9233171B2 (en)
EP (1) EP2794010A4 (en)
JP (1) JP2014533954A (en)
KR (1) KR20140105765A (en)
CN (1) CN104066481A (en)
AU (1) AU2012340686A1 (en)
BR (1) BR112014012155A2 (en)
CA (1) CA2856411A1 (en)
CL (1) CL2014001282A1 (en)
HK (1) HK1201772A1 (en)
IL (1) IL232666D0 (en)
MX (1) MX2014006087A (en)
PH (1) PH12014501119A1 (en)
RU (1) RU2014121820A (en)
SG (1) SG11201402343SA (en)
WO (1) WO2013078271A1 (en)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5828901B2 (en) 2010-10-29 2015-12-09 イミュノジェン, インコーポレイテッド Novel EGFR binding molecule and immunoconjugate thereof
AU2011320318B9 (en) 2010-10-29 2015-11-19 Immunogen, Inc. Non-antagonistic EGFR-binding molecules and immunoconjugates thereof
JP2014533954A (en) 2011-11-21 2014-12-18 イミュノジェン, インコーポレイテッド Method for treating tumors resistant to EGFR therapy with EGFR antibody cytotoxic drug conjugates
CN105473616A (en) * 2013-07-05 2016-04-06 形成生物产品有限公司 Antibody conjugate Egfr
EP3044593A4 (en) * 2013-09-09 2017-05-17 Triact Therapeutics, Inc. Cancer therapy
AU2014348552A1 (en) 2013-11-13 2016-06-02 Zymeworks Inc. Monovalent antigen binding constructs targeting EGFR and/or HER2 and uses thereof
WO2016036861A1 (en) 2014-09-02 2016-03-10 Immunogen, Inc. Methods for formulating antibody drug conjugate compositions
WO2016065456A1 (en) * 2014-10-31 2016-05-06 Formation Biologics Inc. Egfr antibody-based combination therapy
KR101692044B1 (en) * 2014-12-05 2017-01-04 사회복지법인 삼성생명공익재단 Method for Predicting Treatment Effects of EGFR Inhibitor in Glioblastoma
US20180117053A1 (en) * 2015-05-27 2018-05-03 Metastat, Inc. The Method of Use for Inhibitors of Epidermal Growth Factor Receptor Variants II, III and VI
WO2017011618A1 (en) * 2015-07-15 2017-01-19 The Curators Of The University Of Missouri Targeted nanoparticle conjugate and method for co-delivery of sirna and drug
CN107496933A (en) * 2017-08-21 2017-12-22 山东新华制药股份有限公司 It is a kind of to be used to treat antibody drug conjugates of cancer of pancreas and preparation method thereof

Family Cites Families (83)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4307016A (en) 1978-03-24 1981-12-22 Takeda Chemical Industries, Ltd. Demethyl maytansinoids
US4256746A (en) 1978-11-14 1981-03-17 Takeda Chemical Industries Dechloromaytansinoids, their pharmaceutical compositions and method of use
JPS55102583A (en) 1979-01-31 1980-08-05 Takeda Chem Ind Ltd 20-acyloxy-20-demethylmaytansinoid compound
JPS55162791A (en) 1979-06-05 1980-12-18 Takeda Chem Ind Ltd Antibiotic c-15003pnd and its preparation
JPS6253158B2 (en) 1979-09-19 1987-11-09 Takeda Chemical Industries Ltd
JPH0115514B2 (en) 1979-09-21 1989-03-17 Takeda Chemical Industries Ltd
EP0028683A1 (en) 1979-09-21 1981-05-20 Takeda Chemical Industries, Ltd. Antibiotic C-15003 PHO and production thereof
WO1982001188A1 (en) 1980-10-08 1982-04-15 Takeda Chemical Industries Ltd 4,5-deoxymaytansinoide compounds and process for preparing same
US4450254A (en) 1980-11-03 1984-05-22 Standard Oil Company Impact improvement of high nitrile resins
US4315929A (en) 1981-01-27 1982-02-16 The United States Of America As Represented By The Secretary Of Agriculture Method of controlling the European corn borer with trewiasine
US4313946A (en) 1981-01-27 1982-02-02 The United States Of America As Represented By The Secretary Of Agriculture Chemotherapeutically active maytansinoids from Trewia nudiflora
US4563304A (en) 1981-02-27 1986-01-07 Pharmacia Fine Chemicals Ab Pyridine compounds modifying proteins, polypeptides or polysaccharides
JPH0114918B2 (en) 1981-05-20 1989-03-14 Takeda Chemical Industries Ltd
US4943533A (en) 1984-03-01 1990-07-24 The Regents Of The University Of California Hybrid cell lines that produce monoclonal antibodies to epidermal growth factor receptor
US5470571A (en) 1988-01-27 1995-11-28 The Wistar Institute Method of treating human EGF receptor-expressing gliomas using radiolabeled EGF receptor-specific MAB 425
AU4128089A (en) 1988-09-15 1990-03-22 Rorer International (Overseas) Inc. Monoclonal antibodies specific to human epidermal growth factor receptor and therapeutic methods employing same
AU639726B2 (en) 1989-09-08 1993-08-05 Duke University Structural alterations of the egf receptor gene in human gliomas
US5981725A (en) 1989-09-08 1999-11-09 The Johns Hopkins Univiersity Structural alterations of the EGF receptor gene in human tumors
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
US5459061A (en) 1990-01-26 1995-10-17 W. Alton Jones Cell Science Center, Inc. Hybridomas producing monoclonal antibodies which specifically bind to continuous epitope on the human EGF receptor and compete with EGF for binding to the EGF receptor
ES2113940T3 (en) 1990-12-03 1998-05-16 Genentech Inc Method for enrichment of protein variants with altered binding properties.
CZ282603B6 (en) 1991-03-06 1997-08-13 Merck Patent Gesellschaft Mit Beschränkter Haftun G Humanized and chimeric monoclonal antibody, expression vector and pharmaceutical preparation
HU218140B (en) 1991-04-25 2000-06-28 Chugai Seiyaku Kabushiki Kaisha reshaped human antibody against human IL-6 receptor
EP0563475B1 (en) 1992-03-25 2000-05-31 Immunogen Inc Cell binding agent conjugates of derivatives of CC-1065
US5756291A (en) 1992-08-21 1998-05-26 Gilead Sciences, Inc. Aptamers specific for biomolecules and methods of making
DK0659439T3 (en) 1993-12-24 2002-01-14 Merck Patent Gmbh immunoconjugates
AU2071695A (en) 1994-03-17 1995-10-03 Merck Patent Gmbh Anti-EGFR single-chain FVS and anti-EGFR antibodies
CU22545A1 (en) 1994-11-18 1999-03-31 Centro Inmunologia Molecular Obtaining a chimeric and humanized antibody against the epidermal growth factor receptor for diagnostic and therapeutic use
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5942602A (en) 1997-02-13 1999-08-24 Schering Aktiengessellschaft Growth factor receptor antibodies
US6235883B1 (en) 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
EP1033406A4 (en) 1997-10-27 2005-03-09 Sumitomo Electric Industries Inducer for production of antigen-specific antibody, expression vector containing gene therefor, and method of inducing production of antigen-specific antibody
US20040031072A1 (en) 1999-05-06 2004-02-12 La Rosa Thomas J. Soy nucleic acid molecules and other molecules associated with transcription plants and uses thereof for plant improvement
US7303749B1 (en) 1999-10-01 2007-12-04 Immunogen Inc. Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents
USRE43899E1 (en) 1999-10-01 2013-01-01 Immunogen Inc. Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents
CA2385528C (en) 1999-10-01 2013-12-10 Immunogen, Inc. Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents
PT1242401E (en) 1999-11-24 2007-03-30 Immunogen Inc Cytotoxic agents comprising taxanes and their therapeutic use
NZ520622A (en) * 2000-02-25 2004-08-27 Us Gov Health & Human Serv Anti-EGFRvIII scFvs with improved cytotoxicity and yield, immunotoxins based thereon, and methods of use thereof
US7097840B2 (en) 2000-03-16 2006-08-29 Genentech, Inc. Methods of treatment using anti-ErbB antibody-maytansinoid conjugates
US6333410B1 (en) 2000-08-18 2001-12-25 Immunogen, Inc. Process for the preparation and purification of thiol-containing maytansinoids
EP1361893B1 (en) 2001-02-19 2012-10-24 Merck Patent GmbH Modified anti-egfr antibodies with reduced immunogenicity
PT1392359E (en) 2001-05-11 2010-01-27 Ludwig Inst For Cancer Res Ltd Specific binding proteins and uses thereof
US6441163B1 (en) 2001-05-31 2002-08-27 Immunogen, Inc. Methods for preparation of cytotoxic conjugates of maytansinoids and cell binding agents
US7595378B2 (en) 2001-06-13 2009-09-29 Genmab A/S Human monoclonal antibodies to epidermal growth factor receptor (EGFR)
CA2450285C (en) 2001-06-13 2016-08-02 Genmab A/S Human monoclonal antibodies to epidermal growth factor receptor (egfr)
GB0122914D0 (en) 2001-09-22 2001-11-14 Univ Nottingham Modulation of stat activity
US6716821B2 (en) 2001-12-21 2004-04-06 Immunogen Inc. Cytotoxic agents bearing a reactive polyethylene glycol moiety, cytotoxic conjugates comprising polyethylene glycol linking groups, and methods of making and using the same
WO2004094595A2 (en) 2003-04-17 2004-11-04 Alnylam Pharmaceuticals Inc. MODIFIED iRNA AGENTS
AT501173T (en) 2003-12-04 2011-03-15 Abbott Biotherapeutics Corp Anti-ip-10 antibodies
US7276497B2 (en) 2003-05-20 2007-10-02 Immunogen Inc. Cytotoxic agents comprising new maytansinoids
JP4800210B2 (en) 2003-06-27 2011-10-26 アムジエン・フレモント・インコーポレイテツド Antibodies that recognize deletion mutants of epidermal growth factor receptor and uses thereof
CN1930187B (en) * 2003-06-27 2015-08-19 艾默根佛蒙特有限公司 Mutant antibodies and their use thereof for the absence of epidermal growth factor receptor
TWI333977B (en) 2003-09-18 2010-12-01 Symphogen As Method for linking sequences of interest
US8088387B2 (en) 2003-10-10 2012-01-03 Immunogen Inc. Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates
AU2004297616B2 (en) 2003-12-04 2008-12-18 Xencor, Inc. Methods of generating variant proteins with increased host string content and compositions thereof
DK1711530T3 (en) 2003-12-22 2009-12-14 Glaxo Group Ltd Nogo-A neutralizing immunoglobulins for the treatment of neurological disorders
AU2005224267B2 (en) 2004-03-19 2011-07-21 Imclone Llc Human anti-epidermal growth factor receptor antibody
DK2423331T3 (en) * 2004-03-31 2019-07-29 Massachusetts Gen Hospital Procedure for determining the reactivity of cancer on treatments targeted against epidermal growth factor receptor
NZ579482A (en) 2004-06-01 2011-02-25 Genentech Inc Antibody drug conjugates and methods
US20070009972A1 (en) 2005-02-16 2007-01-11 Ginger Chao Epidermal growth factor receptor polypeptides and antibodies
WO2006113623A2 (en) 2005-04-15 2006-10-26 Immunogen, Inc. Elimination of heterogeneous or mixed cell population in tumors
US8101183B2 (en) 2005-05-06 2012-01-24 Zymogentics, Inc. Variable region sequences of IL-31 monoclonal antibodies
US20070213292A1 (en) 2005-08-10 2007-09-13 The Rockefeller University Chemically modified oligonucleotides for use in modulating micro RNA and uses thereof
US20090258442A1 (en) 2006-08-31 2009-10-15 Cell Signaling Technology, Inc. Reagents for the detection of protein phosphorylation in carcinoma signaling pathways
US20090252681A1 (en) 2005-10-11 2009-10-08 Ablynx N.V. Nanobodies and Polypeptides Against EGFR and IGF-IR
AT530578T (en) 2006-08-11 2011-11-15 Schering Corp Antibodies to il-17a
CN104013956B (en) * 2007-01-25 2018-12-18 达娜-法勃肿瘤研究所公司 Purposes of the anti-egfr antibodies in the mutant mediated disease for the treatment of EGFR
WO2008098145A1 (en) 2007-02-07 2008-08-14 University Of Washington Methods for modulating antigen-specific b cell responses
EP2132229B1 (en) 2007-03-01 2016-05-11 Symphogen A/S Recombinant anti-epidermal growth factor receptor antibody compositions
US7892777B2 (en) 2007-07-17 2011-02-22 The Regents Of The University Of Michigan Methods for measuring whether a treatment affects RPTP-κ activity
EP2190878A1 (en) 2007-09-06 2010-06-02 Genmab A/S Novel methods and antibodies for treating cancer
US20090269343A1 (en) * 2008-04-11 2009-10-29 Duke University Dual Specific Immunotoxin for Brain Tumor Therapy
UA108598C2 (en) 2008-04-30 2015-05-25 Highly conjugates and hydrophilic crosslinking agents (linkers)
RU2503687C2 (en) 2008-04-30 2014-01-10 Иммьюноджен, Инк. Stitching reagents and their use
WO2010009124A2 (en) 2008-07-15 2010-01-21 Genentech, Inc. Anthracycline derivative conjugates, process for their preparation and their use as antitumor compounds
WO2010022736A2 (en) 2008-08-29 2010-03-04 Symphogen A/S Recombinant anti-epidermal growth factor receptor antibody compositions
AU2009303318B2 (en) 2008-10-10 2016-06-30 Aptevo Research And Development Llc TCR complex immunotherapeutics
EP2359852A4 (en) 2008-11-17 2015-05-20 Nat Cancer Ct Novel cancer targeting therapy using complex of substance capable of binding specifically to constituent factor of cancer stroma and anti-tumor compound
EP2486023A4 (en) * 2009-10-06 2014-05-07 Immunogen Inc Potent conjugates and hydrophilic linkers
EP2573175A4 (en) 2010-05-18 2014-05-14 Medical & Biol Lab Co Ltd ANTIBODY CAPABLE OF BINDING TO TRANSFORMING GROWTH FACTOR ALPHA AND HAVING ANTIPROLIFERATIVE ACTIVITY ON CANCER HAVING Ras GENE MUTATION
AU2011320318B9 (en) 2010-10-29 2015-11-19 Immunogen, Inc. Non-antagonistic EGFR-binding molecules and immunoconjugates thereof
JP5828901B2 (en) 2010-10-29 2015-12-09 イミュノジェン, インコーポレイテッド Novel EGFR binding molecule and immunoconjugate thereof
JP2014533954A (en) 2011-11-21 2014-12-18 イミュノジェン, インコーポレイテッド Method for treating tumors resistant to EGFR therapy with EGFR antibody cytotoxic drug conjugates

Also Published As

Publication number Publication date
AU2012340686A1 (en) 2014-06-19
CN104066481A (en) 2014-09-24
HK1201772A1 (en) 2015-09-11
EP2794010A1 (en) 2014-10-29
EP2794010A4 (en) 2015-10-21
CL2014001282A1 (en) 2014-11-14
WO2013078271A1 (en) 2013-05-30
US9233171B2 (en) 2016-01-12
PH12014501119A1 (en) 2014-08-04
US20130156796A1 (en) 2013-06-20
KR20140105765A (en) 2014-09-02
RU2014121820A (en) 2015-12-27
BR112014012155A2 (en) 2017-05-30
JP2014533954A (en) 2014-12-18
MX2014006087A (en) 2014-08-01
CA2856411A1 (en) 2013-05-30
IL232666D0 (en) 2014-07-31

Similar Documents

Publication Publication Date Title
EP2748199A4 (en) Anti-ox40 antibodies and methods of using the same
TWI561236B (en) Methods of treating cancer
RU2017117634A (en) Methods for producing conjugates
EP2665521A4 (en) Compositions and methods for treating cancer
IL221288D0 (en) Therapeutic methods using anti-cd200 antibodies
BR112014007603A2 (en) cancer treatment methods
EP2785743A4 (en) Anti-ceacam1 recombinant antibodies for cancer therapy
SG11201403062YA (en) Bacterially derived, intact minicells for delivery of therapeutic agents to brain tumors
ZA201308111B (en) Methods for the treatment of cancer and inflammatory diseases using cereblon as a predictor
DK2895156T3 (en) Method for the preparation of therapeutic nanoparticles
IL238254D0 (en) Methods of treating cancer
BR112013025225A2 (en) preparation of maytansinoid antibody conjugates by one-step process
EP2885002A4 (en) T-cell redirecting bispecific antibodies for treatment of disease
ZA201208820B (en) Combination therapy methods for treating proliferative diseases
IL232344A (en) Combinational lipsosome compositions for cancer therapy
IL232128A (en) Tor kinase inhibitors for treatment of cancer
EP2751570A4 (en) Methods and compositions for the treatment and diagnosis of cancer
PT2694106T (en) Methods for increasing efficacy of folr1 cancer therapy
EP2744830A4 (en) Lsr antibodies, and uses thereof for treatment of cancer
DK2681227T3 (en) Phosphoramidate derivatives of 5-fluor-2'-deoxyuridine for use in cancer treatment
BR112014001440A2 (en) New Compositions and Methods for the Treatment of Prostate Cancer
DK2766040T3 (en) Pertuzumab, trastuzumab, docetaxel and carboplatin for the treatment of early breast cancer
EP2667714A4 (en) Process for the preparation of 4-amino-5-fluoro-3-halo-6-(substituted)picolinates
EP2714081A4 (en) Methods, compositions, and kits for the treatment of cancer
IL237558D0 (en) Methods for the treatment of locally advanced breast cancer